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The present thesis is structured in the following way: 
 
First, a Summary consisting in a brief description of the thesis will be presented. 
 
In Chapter I, Introduction, a general introduction giving the background of the thesis is 
presented. The relevance of gastric cancer in the World and in Portugal is highlighted. 
Also, the two pathways for gastric cancer development (intestinal vs diffuse) as well 
the knowledge about familial aggregation and early-onset gastric cancer will be 
addressed. Risk factors including Helicobacter pylori infection and host genetic 
variations as well premalignant lesions of the stomach will be reviewed. In Rationale 
and Aims, the rationale of this thesis will be described. 
 
In Chapter II, Selection of Patients and Controls, a description of selection of patients 
is described. Additionally an original paper addressing methodology issues regarding 
the validity of the type of selected controls is included. It was the basis for the case-
control design of the study and a support to discuss expected bias. 
 
In Chapter III, Premalignant Conditions and Lesions and Classification Systems in First 
Degree Relatives of Early-Onset Gastric Carcinoma Patients, an original paper was 
included describing the high prevalence of premalignant lesions in cases is described. 
Additionally, we graded and compared the stages of the premalignant lesions using 
OLGA staging system, the newly described OLGIM system and also with an original 
classification system which excludes incisura angularis biopsy.  
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Chapter IV, Host and Helicobacter pylori genotypes in First Degree Relatives of Early-
Onset Gastric Carcinoma Patients, consists in an original paper which represents the 
“in depth” study and search for the explanation of the high risk phenotype previously 
shown. Here we describe the case-specific host genetic variations (regarding 
inflammatory host response) including the traditional described polymorphisms (1β-
511 and IL-1RN) and a new one which can be population specific (IFNGR1). We 
analyzed also H. pylori known specific virulence factors (CagA, VacA s and VacA m). 
 
In Chapter V, Discussion and Concluding Remarks, an overall discussion of all the 
articles will be provided and a general conclusion will be presented. 
 
In Chapter VI, Future Studies, as new answers came with the present work new 
questions emerged and potential lines of investigation are stressed. 
 
The Appendix consists in two original publications in which the author actively 
participated and are related to the content of the thesis. The first one concerns in the 
first international guidelines on follow-up of premalignant conditions and lesions of 
the stomach. The content of this dissertation is closely related to the evidence that 
constituted the basis for grading evidence in the aforementioned guidelines, namely 
familial aggregation of gastric cancer, host and H.pylori genetic variations and 
premalignant conditions and lesions sampling and grading (Appendix 1). The second 
publication is based on endoscopic classification of different patterns of gastric mucosa 
and its correspondence to histology. It opens the way to further research on its 
validation and correlation to the classical histological-based staging systems (Appendix 
2). 
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INTRODUCTION 
Gastric cancer is the fourth most common malignancy in the world. In Portugal, gastric 
cancer ranks in fifth place in incidence and mortality for both sexes and its prevalence 
is expected to rise in the next years.  
Intestinal type is more frequently observed in older patients and represents the end 
product of a “cascade” of events that begin with multifocal atrophic gastritis after 
exposure to environmental risk factors like Helicobacter pylori (H. pylori) infection. This 
is usually accompanied by intestinal metaplasia and leds to cancer via dysplasia. This 
lengthy process, commonly known as “Correa Cascade”, is dependent on continued 
chronic inflammation.  
Unlike intestinal gastric cancer, the diffuse type typically develops following chronic 
inflammation without passing through the intermediate steps.  
H. pylori infection is a pivotal risk factor for gastric cancer development with tumor 
progression occurring only in a subset of individuals most probably these with genetic 
susceptibility and infected by virulent strains of H. pylori. Several studies showed that 
gastric cancer risk increases in patients with extensive intragastric premalignant 
conditions (eg, detection both in the antrum and the corpus) which is determined by 
biopsy sampling with histological assessment according to Sydney System. The recently 
established OLGA staging system (Operative Link for Gastritis Assessment) aims to 
translate the pathological data into a standardized report with information on the 
gastric condition (topography and extent of the atrophic changes) and subgrouping 
patients by cancer risk. Acknowledging the fact that severity and extension of atrophy 
remain the main parameters for grading and the interobserver agreement is low, a 
modified OLGA system (OLGIM) was introduced based on intestinal metaplasia and 
proved to have a better level of interobserver concordance. 
Familial clustering of gastric cancer may be caused by genetic susceptibility but may 
also occur because of nonhereditary factors, such as exposure to H. pylori, smoking or 
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to a common diet. It is known that in 10% of gastric cancers there is familial 
aggregation, suggesting some kind of familial predisposition. The significance of family 
history and familial clustering of gastric cancer is not clearly determined.  
Early-onset gastric cancer (EOCG) is defined as gastric cancer presenting at the age of 
45 or younger; approximately 10% of gastric cancer patients fall into the EOCG 
category. It is postulated that genetic factors may be more important in EOCG than in 
older patients but environmental factors, such as H.pylori infection, may also play a 
role in the development of the disease in young patients. The occurrence of gastric 
cancer in young patients remains largely unexplained, and it has been suggested to be 
due to the inter-across between a predisposing genotype and environmental 
“triggers”. Relatives of EOGC patients were seldom studied. 
 
AIMS 
To characterize the first degree relatives (FDRs) of early-onset gastric cancer (EOGC) 
patients regarding histological features of gastric mucosa, genetic susceptibility and 
virulence of H.pylori strains.  
To assess OLGA staging system in the stratification of patients according to their 
cancer risk as well as OLGIM staging system and OLGA and OLGIM modified systems 
(excluding incisura angularis biopsies). 
 
METHODS 
A case control study was conducted with FDRs of EOGC patients (cases; n=103) and age 
and gender matched controls (n=101; mean age 43 years old; 41% males; ranging from 
spouses (n=25) to neighbors (n=25) and dyspeptics (n=51)).  
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Upper GI endoscopy with Sydney-Houston biopsy protocol was performed and OLGA 
system used for staging and OLGIM used for staging as well as modified versions with 
exclusion of the biopsies from incisura angularis in the analysis. Culture and 
genotyping of H. pylori strains (cagA and vacA m and s regions) and host IL1B -511, 
IL1RN intron2 VNTR and IFNGR1-56 genotyping was performed. 
 
RESULTS 
Seventy percent of FDRs of EOGC (cases) showed atrophy (OLGA stage I-IV) while 19% 
presented with high stage gastritis (OLGA stage III or IV) (p<0.001) and gastric dysplasia 
was present in 7 individuals (vs none in controls) (p=0.007). The application of OLGIM, 
modified OLGA and modified OLGIM classifications led to downgrade of stages in 
comparison with the original OLGA classification (27%, 15% and 30% respectively). In 
all classification systems, dysplastic lesions clustered (86%) in high-risk stages. In cases, 
H. pylori was present in 82% (vs 62% in controls; p=0.004) with vacA s1/m1 + strains 
significantly associated with the presence of atrophy in gastric mucosa; also, in 
individuals homozygous for IL1B–511*T a significantly higher risk was shown for 
advanced OLGA stages and dysplasia.  An increased global prevalence of IFNGR1-
56*T/*T polymorphism (37% in cases vs 24% in controls; p=0.03) was observed with no 
association with atrophic changes or dysplasia. All trends observed were kept when 
comparing FDRs of EOGC with spouses, neighbors or dyspeptic controls. 
 
CONCLUSIONS 
 FDRs of EOGC patients have an increased prevalence of high risk OLGA stages and 
dysplasia that seem to be associated with high-risk H. pylori strains and pro-
inflammatory host genotypes, respectively.  FDRs of EOGC patients may merit specific 
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management through H. pylori eradication and endoscopic/histopathological adequate 
assessment of gastric mucosa and surveillance. 
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INTRODUÇÃO 
O cancro gástrico é a quarta neoplasia mais frequente no Mundo. Em Portugal o 
cancro gástrico situa-se na quinta posição em incidência e mortalidade para ambos os 
sexos e espera-se que a sua prevalência aumente nos próximos anos.  
O tipo intestinal é mais frequente em doentes com idade avançada e representa o 
culminar de uma “cascata” de eventos com início na gastrite atrófica multifocal após 
exposição a factores de risco ambientais, tal como a infecção por Helicobacter pylori. 
Normalmente estas alterações são acompanhadas por metaplasia intestinal dando 
origem ao cancro o qual é precedido por displasia. Este processo lento, conhecido 
como a “cascata de Correa” é dependente de inflamação crónica continuada.  
Ao contrário do cancro de tipo intestinal, o tipo difuso desenvolve-se em contexto de 
inflamação crónica sem passar pelas etapas intermédias.  
A infecção por H. pylori é um factor de risco crucial para o desenvolvimento de cancro 
com a progressão para neoplasia ocorrendo apenas numa pequena parte dos 
indivíduos infectados, provavelmente naqueles com susceptibilidade genética em 
associação com estirpes virulentas da bactéria.  
Vários estudos demonstraram que o risco de cancro gástrico está aumentado nos 
indivíduos com condições prémalignas gástricas extensas (detectadas no antro e corpo 
simultaneamente) o que é determinado por amostras colhidas por biopsias com 
avaliação histológica de acordo com o Sistema de classificação de Sydney. O sistema de 
classificação OLGA (Operative Link for Gastritis Assessment) recentemente proposto 
tem como objectivo a translação dos dados anatomopatológicos das condições 
prémalignas (topografia e extensão da atrofia) para um sistema de graduação que 
agrupa os doentes por risco de desenvolvimento de cancro gástrico. Tendo em conta 
que a extensão e a severidade da atrofia são os parâmetros em avaliação e que a 
concordância interobservador para atrofia é baixa foi proposto um novo sistema de 
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classificação baseado na avaliação da metaplasia intestinal, com um melhor nível de 
concordância (OLGIM). 
A agregação familiar de cancro gástrico pode ser secundária a susceptibilidade 
genética mas factores não hereditários poderão também estar implicados tais como a 
infecção por H. pylori, exposição a tabaco ou ao mesmo tipo de dieta. É reconhecido 
que cerca de 10% dos cancros gástricos têm agregação familiar, sugerindo uma forma 
de predisposição familiar. O significado desta agregação e da história familiar não está 
claramente elucidado.  
O cancro gástrico precoce (CGP) é definido pelo desenvolvimento de cancro antes dos 
45 anos de idade; aproximadamente 10% dos cancros pertencem a este subgrupo. 
Acredita-se que os factores genéticos terão mais relevância nesta subpopulação do 
que nos doentes com cancro em idade avançada, mas os factores ambientais tal como 
a infecção a H. pylori poderão também ser importantes no desenvolvimento da doença 
em doentes jovens. O motivo da ocorrência da doença nestes doentes jovens 
permanece largamente inexplicado podendo corresponder a uma interacção entre um 
genótipo com predisposição e factores desencadeantes ambientais. Não há estudos 
em familiares de doentes com CGP. 
 
OBJECTIVOS 
Caracterizar os familiares de primeiro grau (FPG) de doentes com cancro gástrico 
precoce (CGP) em relação a parâmetros histológicos da mucosa gástrica, 
susceptibilidade genética e virulência das estirpes de H. pylori. Estudar o sistema de 
classificação OLGA na estratificação segundo o risco de cancro assim como o sistema 
OLGIM e os dois sistemas modificados (excluindo a biopsia da incisura angularis). 
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MÉTODOS 
Procedeu-se a um estudo caso-controlo com FPG de doentes com CGP (casos; n=103) e 
controlos emparelhados para o sexo e idade (n=101; idade média 43 anos; 41% sexo 
masculino; englobando cônjuges (n=25), vizinhos (n=25) e doentes dispépticos (n=51)). 
Foi efectuada endoscopia digestiva alta com biopsias segundo o protocolo de Sydney-
Houston e estadiamento segundo os sistemas OLGA, OLGIM e os mesmos modificados 
com exclusão da biopsia da incisura. Procedeu-se à cultura e genotipagem  das estirpes 
de H. pylori (cagA e regiões m e s vacA) assim como à genotipagem do hospedeiro 
relativamente aos genes IL1B -511, IL1RN e IFNGR1-56. 
 
RESULTADOS 
Setenta por cento dos FPG de CGP apresentaram atrofia (Estadios OLGA I-IV) com 19% 
deles com estádio avançado (Estadios OLGA III-IV) (p<0.001) com 7 displasias nos casos 
e nenhuma nos controlos (p=0.007). A aplicação dos sistemas OLGIM e OLGA e OLGIM 
modificados levou ao infraestadiamento de estadios em comparação com a 
classificação OLGA (27%, 15% e 30%, respectivamente). Em todos os sistemas de 
classificação, 86% das displasias agruparam-se nos grupos de alto risco. A infecção por 
H. pylori foi diagnosticada em 82% dos casos e 62% dos controlos (p=0.004), com as 
estirpes vacA s1/m1 + significativamente associadas à presença de atrofia na mucosa 
gástrica. Adicionalmente foi demonstrado que a homozigotia para IL1B–511*T conferia 
um maior risco para estadios OLGA avançados e displasia. Um aumento de prevalência 
global do polimorfismo IFNGR1-56*T/*T foi observado nos casos (37% nos casos vs 
24% nos controlos; p=0.03), sem relação com estadios de atrofia ou presença de 
displasia. Todas as diferenças observadas se mantiveram quando a comparação foi 
efectuada com os diferentes tipos de controlos: cônjuges, vizinhos ou dispépticos. 
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CONCLUSÕES 
FPG de doentes com CGP têm uma elevada prevalência de estadios OLGA de risco e 
displasia os quais parecem estar associados a estirpes de risco de H. pylori e genótipos 
pró-inflamatórios do hospedeiro. FPG de doentes com CGP poderão ser alvo de 
orientação diferenciada com erradicação de H. pylori e avaliação endoscópica e 
histológica da mucosa gástrica e vigilância. 
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IA.1. Epidemiology of Gastric Cancer 
Gastric cancer is one of the most common cancers with about one million new cases 
estimated to have occurred in 2008 (988 000 cases, 7.8% of the total), making it the 
fourth most common malignancy in the world, behind cancers of the lung, breast and 
colo-rectum. More than 70% of cases (713 000 cases) occur in developing countries 
(467 000 in men, 246 000 in women), and half the world total occurs in Eastern Asia. 
Age-standardized incidence rates are about twice as high in men as in women, ranging 
from 3.9 in Northern Africa to 42.4 in Eastern Asia for men, and from 2.2 in Southern 
Africa to 18.3 in Eastern Asia for women (Globocan 2008). The worldwide incidence of 
gastric cancer has declined rapidly over the recent few decades (Anderson et al. 2010, 
Jemal et al. 2006, Schlansky et al. 2011). Part of the decline may be due to the 
decrease of certain risk factors such as Helicobacter pylori infection and other dietary 
and environmental risks. The decline first took place in countries with low gastric 
cancer incidence as the United States (Schlansky et al. 2011), while the decline in 
countries with high incidence, like Japan, occurred later and was slower (Hirayama 
1975).   
Gastric cancer used to be the leading cause of cancer deaths in the world until the 
1980s when it was overtaken by lung cancer (Pisani et al. 1993). Nowadays, stomach 
cancer is the second leading cause of cancer death in both sexes worldwide (736 000 
deaths, 9.7% of the total) with only a minority of gastric adenocarcinomas diagnosed 
at a curable and ressectable stage. Most patients die during the first year after the 
diagnosis, even if submitted to costly and aggressive therapy (Diaz De Liano et al. 
2003). The highest mortality rates are estimated in Eastern Asia (28.1 per 100,000 in 
men, 13.0 per 100,000 in women), the lowest in Northern America (2.8 and 1.5 
respectively). High mortality rates are also present in both sexes in Central and Eastern 
Europe, and in Central and South America.  
In Portugal, gastric cancer ranks in 5th place in incidence and mortality for both sexes 
after prostate, breast, colo-rectum and lung cancers. In spite of worldwide global 
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decrease, in 2020 (using computing models), the prevalence of gastric cancer is 
expected to rise in Portugal, for both sexes. 
 
Figure1. Expected prevalence of gastric cancer in Portugal in 2020 using age-specific 
rates and corresponding populations for 10 age-groups (From Globocan, 2008). 
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IA.2. Intestinal versus Diffuse: Two Pathways for Gastric Cancer 
Several attempts to classify gastric cancer have been made over the past decades.  The 
most commonly used classifications are the World Health Organization (WHO) 
(Lauwers GY 2010) and the Lauren´s classification, the latter encompassing two main 
histological subtypes, diffuse and intestinal (Lauren 1965), which have different 
profiles regarding epidemiology, precursor lesions and clinic-pathological profile. 
Intestinal adenocarcinomas predominate in the high risk areas whereas the diffuse 
adenocarcinoma is more common in low risk areas (Lauwers GY 2010). Incidence of 
the intestinal type has been decreasing over the past several decades (Henson et al. 
2004, Locke et al. 1995); in low-risk populations, the frequency of intestinal type 
gastric adenocarcinomas is closer to the incidence of diffuse type tumors. 
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Figure2. The two pathways for gastric cancer and associated risk factors. 
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Intestinal type of gastric carcinoma 
Intestinal type is more frequently observed in older patients and follows multifocal 
atrophic gastritis after exposure to environmental risk factors like H.pylori infection. 
This is usually accompanied by intestinal metaplasia and leds to cancer via dysplasia. 
Based on many studies in the past, the morphogenesis of intestinal type tumors is 
considered to be a gradual and stepwise dedifferentiation of intestinal epithelium to 
autonomously growing tumors that form glandular structures resembling those in 
adenocarcinomas of the gut in general (Vauhkonen et al. 2006). This morphogenesis of 
intestinal type tumors makes understandable the observations that atrophic gastritis 
and intestinal metaplasia are common lesions that underlie or accompany these type 
of tumors. The trigger for initiation of this cascade of events is H.pylori infection. While 
the infection usually starts in the infancy or early childhood, there is a long latency 
period, and cancers are clinically diagnosed four or more decades later. During this 
period, a prolonged precancerous process takes place, represented by a “cascade” of 
events with the following well-characterized, sequential histopathologic stages: 
chronic active non-atrophic gastritis, multifocal atrophic gastritis, intestinal metaplasia, 
dysplasia and invasive carcinoma (Correa et al. 1975, Correa 1992).  
This multistage precancerous sequence of events represents a model of carcinogenesis 
that is similar to the adenoma-carcinoma sequence in colorectal cancer (Fearon et al. 
1990). According to this model, progression of morphologic lesions is modulated by 
molecular and epigenetic changes. However, this process in the gastric mucosa seems 
to be more complex (Correa 1992, Yasui et al. 2006). Several regulatory and molecular 
hot spots, including regulation of the cell cycle, DNA repair, cell adhesion, 
angiogenesis, apoptosis and matrix remodeling have been extensively studied in 
gastric cancer. The molecular genetic changes include mainly the activation of 
oncogenes and inactivation of tumor suppressor genes by genetic and epigenetic 
mechanisms. Several oncogenes are overexpressed in various stages of gastric 
carcinogenesis as the early involvement of K-ras mutations (Yasui et al. 2001) and the 
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c-met oncogene (Smith et al. 2006) which expression appears to be modulated by 
virulent H.pylori strains (Churin et al. 2003). On the other hand, approximately 50 
percent of intestinal type gastric cancers have alterations in genes that are thought to 
function as tumor suppressor genes, including TP53 (Yasui et al. 2006), APC 
(adenomatous polyposis coli)(Fang et al. 2002), TTF (trefoil factor family) (Lefebvre et 
al. 1996) and other genes. 
Diffuse type of gastric carcinoma 
Unlike intestinal gastric cancer, the diffuse type typically develops following chronic 
inflammation without passing through the intermediate steps of glandular atrophy and 
intestinal metaplasia. So far, H.pylori gastritis is the only universal precursor condition 
for this subtype of gastric cancer (Weydig et al. 2007). By histology, these tumors 
display poorly-cohesive cells, organized in cords or micro glands as well as well as 
discohesive cells that may invade widely the gastric wall, some of which may be of 
signet ring cell type. Diffuse type cancers disseminate to the peritoneum and gives rise 
to nodal metastases, characterized by rapid disease progression and poor prognosis 
(Yashiro et al. 1995). Unlike the complex and poorly understood molecular pathways 
that underlie carcinogenesis in intestinal type tumors, diffuse carcinomas display a 
major molecular abnormality: defective intercellular adhesions. In most cases, this 
results from loss of expression of the cell adhesion protein E-Cadherin (CDH1) which 
encodes a homodimeric transmembrane cellular adhesion protein; its cytoplasmatic 
tail interacts with catenins, assembling the cell:cell adhesion complex (Graziano et al. 
2003).  
Germline mutations of the CDH1 gene were first described in three Maori families 
from New Zeland that were predisposed to diffuse gastric cancer (Guilford et al. 1998). 
Subsequently germline mutations have been identified in many other kindreds 
worldwide (Gayther et al. 1998, Oliveira et al. 2009) . Hereditary diffuse gastric cancer 
(HDGC) is a genetic disease with an autosomal dominant pattern of inheritance, with 
early onset gastric cancer (gastric cancers diagnosed before 45 years of age)   in the 
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majority of affected individuals. The lifetime cumulative risk for clinically significant 
gastric cancer in individuals from these families is >80% in both men and women by 
age 80 (Fitzgerald et al. 2010). The early gastric cancers that develop in these 
individuals are often multifocal and located beneath an intact mucosal surface 
(Carneiro et al. 2008, Charlton et al. 2004). Because of the difficulty in early detection 
and the poor prognosis of these tumors in patients harboring germline E-cadherin 
mutations, these patients are candidates for prophylactic gastrectomy (Caldas et al. 
1999).  
Abnormal expression of CDH1 has also been linked to sporadic diffuse carcinomas. 
Somatic mutations in CDH1 are identified in 40 to 83% of sporadic diffuse type gastric 
cancers (Humar et al. 2002) . For the remaining, the mechanism that underlies E-
cadherin dysfunction remains poorly understood; recent reports described the 
importance of E-cadherin post-translational modifications by glycosylation and its 
putative regulatory role (Pinho et al. 2009, Pinho et al. 2011).  
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IA.3. Risk Factors for Gastric Cancer 
 
Helicobacter pylori infection 
Significant advances towards the understanding of gastric carcinogenesis have been 
achieved since the identification of H.pylori by Marshall and Warren in 1984 (Marshall 
et al. 1984), and its latter classification as a class I carcinogen by the International 
Agency for Research on Cancer. This organism is now known to cause chronic gastritis, 
most peptic ulcers and gastric lymphoma and adenocarcinoma. Colonization is usually 
asymptomatic and tumor progression only occurs in a subset of individuals and is 
dependent on the host response as well as genetic variation of the bacteria (Atherton 
2006).  
Almost half of the world´s population is infected with the bacteria and infection is 
more frequent and acquired at an earlier age in developing countries where the 
prevalence in adults peaks at more than 80 percent before age 50 (Pounder et al. 
1995). Epidemiologic evidence indicates that most infections are acquired during 
childhood, even in developed countries (Parsonnet 1995). A study on a pediatric 
population from Portugal (aged 0-15 years) found a global prevalence of H.pylori 
infection of 31.6%, increasing with age and similar among genders; 47.5% of children 
acquired infection before 5 years of age (Oleastro et al. 2011). 
H.pylori is a gram-negative micro-aerophilic bacterium whose habitat is the gastric 
epithelium where it lives within or beneath the gastric mucous layer. The bacterium 
generally does not invade the gastrointestinal tissue and is located around intercellular 
epithelial connections and on the surface by producing special adherence structures.  
It renders the underlying mucosa more vulnerable to acid peptic damage by disrupting 
the mucosal layer, liberating enzymes and toxins, and adhering to the gastric 
epithelium. Additionally, the host immune response to H.pylori incites an inflammatory 
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reaction which further perpetuates tissue injury and the clinical outcome should be 
viewed as a complex interaction between the host and the bacterium.  
Functional differences exist between strains of H.pylori that may relate to virulence 
and tissue damage (Mobley 1996). The well characterized virulence factors are 
vacuolating cytotoxin (vacA) and cytotoxin associated gene A (cagA). 
 VacA is a cytotoxin that induces cytoplasmatic vacuolation in gastric cells (Figura et al. 
1989). All H.pylori contain the vacA gene, but not all of them induce vacuolation, 
pointing the existence of genetic variability within vacA. Two major polymorphic 
regions have been identified: the signal region (that may be type s1 or s2) and the 
midregion (type m1 or m2) (Atherton et al. 1995). Malignancy is associated with s1/m1 
strains (Figueiredo et al. 2001). Other vacA polymorphic site designed as the 
intermediate (i) region and two sequence types (i1 and i2) were described (Rhead et al. 
2007). It was demonstrated that s1/m1 strains were exclusively i1 and s2/m2 were 
exclusively i2. 
The most important H.pylori virulence factor is cagA which is delivered into gastric 
epithelial cells through a bacterial type IV secretion system, and interacts with several 
major growth-regulating transduction pathways including the Ras/MEK/ERK pathway 
(Mimuro et al. 2002). In addition, forms of cagA encoding multiple type C EPIYA 
segments (which increase phosphorilation-dependent cagA activity) have been shown 
and the number of cagA EPIYA-C segments relate to cancer amongst Western strains 
(Basso et al. 2008). The clinical relevance of cagA positivity was demonstrated in peptic 
ulcer disease and gastric cancer. Approximately 85 to 100 percent of patients with 
duodenal ulcers have cagA positive strains, compared to 30 to 60 percent of infected 
patients who do not develop ulcers (Weel et al. 1996). On the other hand, a meta-
analysis demonstrated that cagA positive strains are associated with a higher 
frequency of precancerous lesions and gastric cancer (Huang et al. 2003). 
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Other proteins and H.pylori associated virulence factors were also described as BabA, 
OipA, IccA, SabA, SabB, DupA, of which the first three are assotiated with gastric 
cancer (Kusters et al. 2006). 
It has been demonstrated by a recent meta-analysis that eradication of H.pylori has 
the potential to prevent gastric cancer(Fuccio et al. 2009), but most data on the 
preventive effect of eradication were generated in high incidence regions in Asia. The 
only prospective, randomized, placebo-controlled, population-based primary 
prevention study has been performed in China, demonstrating gastric cancer 
developed only in patients with baseline premalignant conditions (gastric atrophy 
and/or intestinal metaplasia), giving the rational for the “point of no return” in the 
cascade of gastric mucosal changes (Wong et al. 2004). 
 
Host susceptibility 
An immensity of genes and genetic variations and its implications in gastric 
carcinogenesis has been addressed although its relevance is not always clear. In the 
last few years, the role of host genetic interleukin polymorphisms has been widely 
studied regarding premalignant lesions and as biomarkers for genetic susceptibility in 
gastric cancer development. The best characterized by population-association studies 
are those respecting the inflammatory response to H.pylori infection and the damage-
induced inflammation of the gastric mucosa leading to mucosal atrophy and 
progression to gastric cancer, mainly IL-1β, IL1 Receptor Antagonist (IL-1RN), IL8, IL10 
and TNF-α. Genetic polymorphisms directly influence inter-individual variation in the 
magnitude of cytokine response and this clearly contributes to an individual´s ultimate 
clinical outcome. Early studies by El-Omar showed an association of gastric cancer risk 
with the genotypes carrying IL-1β-511T, IL-1β-31T and IL-1RN*2/*2 with OR of 2.5, 2.6 
and 3.7 for the homozygotes (El-Omar et al. 2000). Following results were inconsistent 
because of variation of allele frequencies in different ethnic groups, tumor type and 
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location, H.pylori infection, methodologies and quality of studies (Persson et al. 2010, 
Yin et al. 2009). Three powered meta-analyses found an association of IL-1 β and IL-
1RN*2 risk in Caucasians but not in Asians (Camargo et al. 2006, Wang et al. 2007, Xue 
et al. 2010) and another found a null association in both populations (Kamangar et al. 
2006). Another recent meta-analysis (Persson et al. 2010) found an increased cancer 
risk for IL-1RN*2carriers, a risk that was specific to non-Asian populations and for distal 
cancers; the analysis restricted for high-quality studies or H.pylori positive cases and 
controls observed association with the carrier and the homozygosity status. Regarding 
Asian populations, reduced risk was observed with IL-1β -31C carrier status (in high-
quality studies). Caucasian carriers of TNF-α -308A were at an increased risk for gastric 
cancer in a recent meta-analysis (Loh et al. 2009).  
Other than the classic susceptibility genes have been considered for playing a role in 
gastric carcinogenesis. Thye and colleagues performed a genome-wide linkage analysis 
in which they identified a polymorphism in the position -56 of the human interferon γ 
(IFNγ) receptor 1 gene (IFNGR1), associated with an increase in the susceptibility of a 
human host to be infected by H.pylori (Thye et al. 2003). A single study demonstrated 
a relevant role of the IFNGR1 gene in the development of early-onset gastric cancer 
(Canedo et al. 2008). 
The study of host genetics brought a better understanding of disease pathogenesis and 
helped in confirming two key-points: the important role of H.pylori infection in gastric 
carcinogenesis and the role of chronic inflammation with its long-term deleterious 
effects on gastric physiology. However, the heterogeneity of results at the present 
time makes it difficult to translate them into recommendations for daily clinical 
practice. 
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Diet 
There are geographic and ethnic differences in the incidence of gastric cancer around 
the world, as well trends in each population over the time. Emigrants from high-
incidence to low-incidence countries experience a decreased risk of developing gastric 
carcinoma. Such findings strongly suggest that environmental factors have an 
important role in the etiology of gastric cancer and that the exposure to risk factors 
occurs early in life (Haenszel et al. 1972). A variety of dietary factors have been 
implicated as risk factors for gastric cancer. Interestingly, the worldwide decline in 
gastric cancer rates has coincided with the widespread use of refrigeration which 
improved the storage of food reducing salt-based preservation of food and allowed for 
fresh food and vegetables (a source of antioxidants for cancer prevention) to be more 
readily available (Coggon et al. 1989, La Vecchia et al. 1990). Lower temperatures 
reduce the rate of bacterial, fungal and other contaminants of fresh food as well as the 
bacterial formation of nitrites. 
Salt  
Different sources of evidence (ecological, case-control and cohort studies) suggest that 
the risk of gastric cancer increases with a high intake of salt (pickled foods, soy sauce, 
dried and salted meat and fish)(Joossens et al. 1996, Kono et al. 1996, Peleteiro et al. 
2011, Shikata et al. 2006, Tsugane et al. 2007). The American Institute for Cancer 
Research classified salt and its consumption as a probable risk factor for gastric cancer. 
Studies on rodents established a link between high salt intake and gastric mucosa 
damage and susceptibility to carcinogenesis (Takahashi et al. 1984). High salt intake 
has been associated with higher rates of atrophic gastritis in the setting of H.pylori 
infection (Fox et al. 1999). Also, the consumption of salted food appears to increase 
the possibility of persistent H.pylori infection (Fox et al. 1999, Tsugane et al. 1994). In 
addition, a synergistic interaction between H.pylori infection and salted food intake to 
increase the risk of gastric cancer has also been reported in some case-control studies 
(Lee et al. 2003, Machida-Montani et al. 2004). 
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Nitroso compounds 
Much attention has been given to the effects of high nitrate intake. Exposition to 
nitroso compounds come from diet, smoking and other environmental sources as well 
as from endogenous synthesis (40 to 75 per cent of exposure) (Tricker 1997). When 
nitrates are reduced to nitrite by bacteria they can react with other nitrogenated 
substances to form N-nitroso compounds that are known mutagens and carcinogens 
(Oldreive et al. 2001). Studies trying to link N-nitroso exposure to gastric cancer have 
been inconclusive, reflecting the fact that nitrate intake does not necessarily correlate 
with nitrosation levels (Knekt et al. 1999). The risk of gastric cancer associated with 
dietary intake of nitrites and endogenous formation of nitroso compounds was 
investigated in the EPIC study. While there was no association between intake of 
nitrites and gastric cancer risk, endogenous production of N-nitroso compounds was 
significantly associated with non-cardia cancer risk (hazard ratio – 1.42)(Jakszyn et al. 
2006). 
Dietary salt and nitroso compounds appear to exert a synergistic effect with H.pylori in 
animal models of gastric carcinogenesis. Several case-control studies in humans have 
shown a positive association between gastric cancer risk and both salt and dietary 
nitrite intake, although data from prospective studies are conflicting (Shikata et al. 
2006, Tokui et al. 2005, van Loon et al. 1998).  
Other diet compounds 
Data from a large European prospective study (EPIC-EURGAST) failed to show an 
overall association between fruit or vegetable consumption and gastric cancer risk 
(Gonzalez et al. 2006). There was, however, a statistically significant association 
between total dietary vegetable content and the intestinal histological subtype. A non-
significant negative association was observed between cardia cancer risk and citrus 
fruit consumption. The effect of fruit and vegetable intake appeared to be 
independent of H.pylori infection. Cohort studies have not provided consistent results; 
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a meta-analysis found a weak association in the reduction of gastric cancer risk from 
18 percent for a high intake of fruits to 12 percent to a high intake of vegetables (Lunet 
et al. 2005). 
Vitamin C and other antioxidant compounds merit attention as potential mediators of 
a dietary influence in gastric cancer risk. Vitamin C levels are reduced in the serum of 
H.pylori infected individuals and being a free radical scavenger it reduces the 
formation of potentially carcinogenic nitroso compounds (Woodward et al. 2001). 
There is some evidence from case-control studies of a negative association between 
dietary vitamin C and gastric cancer risk (Mayne et al. 2001).  Data from the EPIC 
cohort show a negative correlation between gastric cancer risk and serum vitamin C, 
but not dietary vitamin C intake, and this was unaffected by H.pylori status (Jenab et al. 
2006). 
 
Smoking 
Smoking is an independent risk factor for gastric cancer. Several studies examined the 
relationship between tobacco smoking and gastric cancer risk. A meta-analysis of 40 
studies found that compared with never smokers, current smokers had a 1.5-fold 
increased risk for gastric cancer (cardia and noncardia) and was higher in man 
(Tredaniel et al. 1997). Prospective studies have demonstrated a significant dose-
dependent association between tobacco smoking and gastric cancer risk (Koizumi et al. 
2004, Nishino et al. 2006). In the EPIC cohort, it was estimated that 17.6% of gastric 
cancer in this European population was attributable to cigarette smoking (Gonzalez et 
al. 2003).  
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Other risk factors 
Additional risk factors including other infectious agents besides H.pylori, post gastric 
surgery status, gastric polyps and hormonal factors have been investigated but its 
relevance remains unclear. Epstein-Barr (EBV) virus infection is associated with a 
number of malignancies. It has been estimated that between 5 to 10 percent of gastric 
cancers worldwide are EBV associated cancers trough virus mediated methylation of 
the promoter region of cancer-associated genes (Boysen et al. 2009). EBV related 
gastric cancers demonstrate male predominance, tend to be proximal (near the 
cardia), have lymphocytic infiltration and a favorable prognosis (Kusano et al. 2006). 
There is a recognized increased risk of gastric cancer after gastric surgery with the peak 
incidence 15 to 20 years after the surgery (Tersmette et al. 1990). The Billroth II 
(gastrojejunostomy) with regurgitation of alkaline bile and pancreatic juice carries a 
higher risk than Billroth I procedure (gastroduodenostomy)(Tersmette et al. 1990). 
Obesity is also associated with an increased risk of gastric cancer (cardia and non-
cardia). In a meta-analysis of cohort studies a body mass index > 25 carries a risk of 
gastric cancer of 1.22 among non-Asians (Yang et al. 2009).   
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IA.4. Premalignant Conditions and Lesions of the Stomach 
Intestinal-type gastric cancer typically arises in the setting of chronic gastritis and 
develops through intermediate stages of atrophic gastritis, intestinal metaplasia, 
dysplasia and, finally, cancer. This lengthy process, commonly known as “Correa 
Cascade”, is dependent on persistent chronic inflammation (Correa 1992, Correa et al. 
2007). In this multistep model, H. pylori infection plays a pivotal role causing chronic 
inflammation of the mucosa, which slowly progresses through the premalignant 
conditions (atrophic gastritis and intestinal metaplasia) to premalignant lesions 
(dysplasia) and finally to gastric adenocarcinoma (Correa 1992).  
Atrophic gastritis (AG) is defined as loss of glandular structures of the gastric mucosa. 
This is associated with a loss of specialized cells and thus a reduction of gastric 
secretory function (Dixon et al. 1996). Various classifications of AG have been 
proposed over the years (“A,B and C types”; “difuse antral versus multifocal”), 
however these classifications are difficult to use in clinical practice and suffer from 
considerable interobserver variation (Correa et al. 1992, Strickland et al. 1973, 
Whitehead 1995). Currently, the updated Sydney System is generally used both in 
clinical practice and research (Dixon et al. 1996).  In this classification system several 
features of inflammation, atrophy and intestinal metaplasia need to be assessed 
individually. A visual analogue scale was added to facilitate grading of the individual 
features. The evaluation of most features displays good reproducibility, but agreement 
on the recognition and grading of gastric atrophy remains inadequate (Chen et al. 
1999, el-Zimaity et al. 1996, Offerhaus et al. 1999).  
Metaplasia is defined as “replacement of one type of cell with another type” and in 
stomach, intestinal metaplasia (IM) represents the replacement of gastric columnar 
epithelial cells by intestinal cells. IM is characterized by the presence of intestinal-type, 
mucin-containing goblet cells, Paneth cells and absorptive cells. Several classifications 
of IM have been described; first, histochemically-based methods were used allowing 
the definition of three different types. Type I, or complete IM, containing absorptive 
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enterocytes, Paneth cells, and sialomucin-secreting goblet cells; type II, incomplete IM, 
with co-existence of goblet and columnar cells secreting sialomucins; type III, also 
incomplete IM, with presence of goblet and columnar cells secreting sulphomucins 
(Filipe et al. 1994). Second, using molecular alterations in intestinal metaplasia in 
terms of expression of mucins, a new classification of IM was proposed, encompassing 
two types: complete or intestinal IM, characterized by complete loss of gastric mucin 
markers (MUC1, MUC5AC and MUC6) and gain of the intestinal mucin MUC2 and 
incomplete or gastrointestinal mixed IM, where the intestinal mucin MUC2 is found 
together with maintenance of the gastric mucins (Reis et al. 1999). In spite of the 
recognition of different types of gastric intestinal metaplasia, its differentiation has no 
proven relevance for clinical practice. 
Gastric dysplasia is characterized by morphologic alterations in cells and glandular 
arrangement. Assessment of dysplasia is often difficult and interobserver agreement in 
grading dysplasia is poor. In 2000, the unified Padova classification was proposed, 
which divided dysplasia and adenocarcinoma into five categories. The Vienna 
classification further subdivided the categories of low-grade dysplasia and high grade 
dysplasia and was revised to improve the correlation with clinical management (Dixon 
2002, Schlemper et al. 2000). Recently, in an attempt to standardize terminology for 
the morphological spectrum of the lesions, the World Health Organization (WHO) 
proposed a 5 category classification system for gastric dysplasia/intraepithelial 
neoplasia(Lauwers GY 2010). 
After the recognition of the morphologic changes of gastric mucosa that represent the 
background for gastric cancer development, several studies documented the rate of 
progression of these premalignant conditions/lesions. Rates of progression of AG and 
IM vary between 0% to 1.8% and 0% to 10% per year, respectively (de Vries et al. 2007, 
de Vries et al. 2008). The risk of gastric cancer is, generally, too low for patients who 
simply display these alterations; additional risk factors were defined as the intragastric 
extension of AG and IM. Several studies showed that gastric cancer risk increases in 
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patients with extensive intragastric premalignant conditions (eg, detection both in the 
antrum and corpus)(Dinis-Ribeiro 2004, Morson 1955, Vannella et al. 2010). To 
determine the extension of AG and IM three main methods can be used: biopsy 
sampling with histological assessment according to Sydney System (Dixon et al. 1996); 
serology by determination of pepsinogen I and pespinogen I/II ratio (Dinis-Ribeiro et al. 
2004); endoscopic assessment using Kimura classification (not widely used)(Kimura et 
al. 1996).  
  
Staging  
 Biopsy Sampling 
Biopsy specimens of the stomach are essential for the classification and grading of 
preneoplastic gastric lesions. The Sydney and the updated Sydney System for 
classification and grading of gastritis are the most widely accepted (Dixon et al. 1996). 
They were primarily designed to provide standardization for reports of gastric biopsies. 
The updated version recommended five biopsies, one from incisura, two from the 
antrum (3cm from the pylorus, greater and lesser curvatures ) and two from the 
corpus (one from lesser curvature, 4cm proximal to the incisura, and one from the 
middle of the greater curvature), sites that were arbitrarily chosen. Although this 
biopsy protocol is useful for establishing H. pylori status and chronic gastritis 
classification, the number of biopsies is controversial for an adequate staging of 
premalignant gastric lesions mainly because of their multifocal nature (El-Zimaity et al. 
1999, Eriksson et al. 2005, Guarner 2003, Rugge et al. 2005). This multifocality 
influences the ability to detect them, which may affect decisions regarding the 
patient´s therapy or future surveillance (Correa 1988, Correa 1992). 
Some studies  addressed the number of biopsies needed for a precise grading of 
gastritis and preneoplastic lesions and concluded that the Sydney System was 
unreliable, underestimating the presence of intestinal metaplasia corpus atrophy and 
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recommended a minimum of eight biopsies. Other studies concluded that the Sydney 
protocol was sensitive for identification of H.pylori infection and preneoplastic lesions 
(in regions of high prevalence of gastric cancer) (de Vries et al. 2010, El-Zimaity et al. 
1999, Eriksson et al. 2005, Guarner 2003, Satoh et al. 1998). 
Incisura angularis is the location where atrophic/metaplasic changes first appear. 
However, the value of biopsy of incisura angularis has raised some controversy 
(Ricuarte 2005, Rugge 2003), some studies showing that few histological findings are 
detectable in biopsies of the incisura (Eriksson et al. 2005, Satoh et al. 1998)  
Even when extensive biopsy protocols are used inevitable sampling errors may affect 
the identification of the premalignant lesions which are frequently patchy (Dixon et al. 
1996, El-Zimaity et al. 1995, El-Zimaity et al. 1999, El-Zimaity et al. 2002) and can be 
missed on follow-up (El-Zimaity et al. 2001). It is expectable that a low number of 
biopsies will be enough for an accurate diagnosis/staging in high-risk populations 
where the extension of the lesions is wider (Dursun et al. 2004, Satoh et al. 1998, You 
et al. 1993). 
Although the Sydney system and the updated Sydney system (Dixon et al. 1996) 
contributed to the uniformity of the reporting of gastric preneoplastic lesions, no 
information is provided regarding cancer risk. The recently established OLGA staging 
system (Operative Link for Gastritis Assessment) aims to translate the pathological 
data into a standardized report with information on the gastric condition (topography 
and extent of the atrophic changes) and subgrouping patients by cancer risk-Figure 3 
(Rugge et al. 2005, Rugge et al. 2008). Initially, two cross-sectional validation studies 
concluded that OLGA provides relevant clinical information allowing the identification 
of a subpopulation of patients (OLGA stage III/IV) with high risk for gastric cancer who 
were amenable for surveillance(Rugge et al. 2007, Satoh et al. 2008). Recently, Rugge 
(Rugge et al. 2010) described a 12 year follow-up of premalignant gastric lesions with 
OLGA classification at the beginning of the study stratifying patients according to their 
cancer risks. The majority of the patients were “low-stage” (0,I,II) gastritis, and all 
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invasive neoplasia (n=2) were associated with high-risk (III/IV) OLGA stages at 
enrolment (P=0.001;RR=18.56).  Acknowledging  the fact that severity and extension of 
atrophy remain the main parameters for grading and the interobserver agreement is 
low (Dixon et al. 1996, el-Zimaity et al. 1996), Capelle and colleagues introduced a 
modified OLGA system (OLGIM) based on intestinal metaplasia (Capelle et al. 2010). 
This system proved to have a high level of interobserver concordance (Guarner et al. 
1999). The agreement between pathologists was moderate for atrophy (k=0.6) and 
higher for intestinal metaplasia (k = 0.9). The cancer risk was downgraded applying 
OLGIM with fewer patient in high risk stages (III/IV) which, in theory, would select a 
smaller population for whom surveillance would be considered. More studies on 
feasibility and reproducibility in different epidemiological contexts are needed to 
validate these classification systems (Rugge et al. 2007). Recent guidelines on 
management of precancerous conditions and lesions on stomach recommended that 
at least four biopsies (two in antrum and two in corpus; greater and lesser curvature) 
are adequate for the diagnosis and surveillance of premalignant gastric lesions(Dinis-
Ribeiro et al. 2012). These guidelines state also that systems for histopathological 
staging (e.g. OLGA and OLGIM) may be useful for categorization of the risk of 
progression to gastric cancer. 
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Figure 3. OLGA-staging system: the stage of gastritis combines  the atrophy scores obtained in 
antral and oxyntic biopsy samples (adapted from (Rugge et al. 2008)) 
 
Endoscopic Assessment 
Traditionally, endoscopic assessment of biopsy-diagnosed gastric premalignant 
conditions and lesions has been considered to have high interobserver variability and a 
poor correlation with endoscopic findings (Laine et al. 1995, Sauerbruch et al. 1984). 
For the identification of atrophic gastritis, Kimura classification was proposed 
(conventional with light endoscopy) (Kimura et al. 1996), but this method requires 
considerable experience and it not widely used. 
New endoscopic imaging equipments and methods make it possible to detect subtle 
mucosal features not visible with conventional endoscopy, which may improve the 
identification and characterization of these premalignant lesions and help to target 
biopsy sampling. This might allow a more accurate screening, follow-up of high risk 
groups and, eventually, the diagnosis of early neoplasia amenable of endoscopic 
resection. Firstly, chromoendoscopy was used for early detection of malignancies 
within the stomach using different stains (absorptive stain – methilene blue or contrast 
stain – indigo carmine) applied to the surface of gastric mucosa. Chromoendoscopy   
can be used to stain subtle irregularities and to improve the characterization of lesions 
(Kiesslich et al. 2006). Reports on methilene blue magnification chromoendoscopy 
shown validity and good reproducibility in the diagnosis of intestinal metaplasia and 
dysplasia (Areia et al. 2008, Dinis-Ribeiro et al. 2003). However, the use of this 
technique for the diagnosis of neoplasia in the stomach lengthens the time of the 
endoscopic procedure and adds to the workload of gastroenterology departments.  
New endoscopic technologies as Narrow Band Imaging (NBI) provide real-time, on 
demand, enhancing visualization of the vascular network and surface structure of the 
mucosa. These optic light filters based techniques are considered as potential 
alternatives to chromoendoscopy (Muto et al. 2005). Classification of NBI mucosal 
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patterns has been described for various conditions with but are not yet standardized 
or validated sufficiently for use in routine clinical practice. Additionally, there is no 
agreement on which NBI patterns are associated with gastric precancerous lesions. 
The NBI classification systems varied between studies, there was no external 
validation, and reproducibility was not systematically evaluated (Bansal et al. 2008, 
Higashi et al. 2010, Tahara et al. 2009). 
 
 Non-invasive staging 
  Serum pepsinogens 
Serum pepsinogens (PG) correlate with gastric mucosal atrophy and can be divided in 
two types depending on the gastric type of mucosal glandules. PGI and PGII are 
secreted by chief cells (corpus/fundus mucosa). PGII is secreted also by the pyloric 
glands and the proximal duodenal mucosa. Inflammation of the gastric mucosa leads 
to an increase in both PGI and PGII serum levels, usually with a more marked increase 
of PGII and thus a decrease in the PGI/II ratio. With the development of atrophy and 
loss of specialized cells, both PGI and PGII may decrease, but PGI usually shows a more 
marked decrease than PGII, thus there is a further decline in the PGI/II ratio (Kuipers 
2003). A meta-analisys of cross-sectional studies concluded that a combination of 
PGI<50ng/mL and a PGI/PGII ratio<3.0 provided the best results, with a sensitivity of 
65%, a specificity of 74%–85% and a negative predictive value >95%(Dinis-Ribeiro et al. 
2004). Cohort studies, including a Northern Portuguese population, validated these 
results (Dinis-Ribeiro et al. 2007, Oishi et al. 2006, Yanaoka et al. 2008). Nevertheless, 
most studies came from Asian countries, namely Japan, and have regional variations 
which can require cutoff adjustment. 
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IA.5. Family History and Gastric Cancer Risk 
It has long been recognized that 10% of gastric cancers harbor familial aggregation, 
suggesting some kind of familial predisposition. Of these, only 1-3% belongs to 
inherited familial syndromes such as Hereditary Diffuse Gastric Cancer (HDGC) 
(Fitzgerald et al. 2010, Pharoah et al. 2001) and other syndromes in which gastric 
cancer is one of its minor phenotypes, such as Lynch syndrome(Watson et al. 2008), 
Familial Adenomatous Polyposis (Offerhaus et al. 1992) and Peutz-Jeghers syndrome 
(Giardiello et al. 2000).  In these syndromes, the genetic defects, most implicating 
germline mutations of key carcinogenic genes, are well described. For the remaining 
cases, the causes of familial clustering of gastric cancer are not fully elucidated. The 
relevance of family history as a risk factor for gastric cancer is most readily evaluated 
using a case-control approach. It was demonstrated that having a first-degree relative 
with gastric cancer is a risk factor for gastric cancer with odds ratio (OR) varying from 2 
to 10, according to the geographic region and ethnicity (Yaghoobi et al. 2009). Large 
studies conferred an OR of 10.1 for siblings of gastric cancer patients in Turkey; 
nevertheless, the results were not adjusted for environmental factors (Bakir et al. 
2000). Other European (OR-1.8-3.5), American (OR-2.2) and Asiatic (OR-1.5-9.9) case-
control studies corroborated that family history of gastric cancer is a risk factor for 
developing the disease (Dhillon et al. 2001, Eto et al. 2006, Foschi et al. 2008, García-
González et al. 2007, Hong et al. 2006, Minami et al. 2003, Palli et al. 1994, Vecchia et 
al. 1992). Even after adjustment for environmental factors the risk was not altered. 
Interestingly, Lauren intestinal type of gastric cancer was strongly associated with the 
family history of gastric cancer when compared with the diffuse type (Bernini et al. 
2006, Eto et al. 2006).  
Familial relative risk is a hallmark of genetic susceptibility. Familial clustering may also 
be caused by nonhereditary factors, such as exposure to H. Pylori, smoking or to a 
common diet. It is also possible that a gene/environment interaction is involved – this 
would be the case when genetic susceptibility to infection or the mutagenic effects of 
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smoking (or another carcinogen) were responsible for the observed familial 
association. A pivotal case-control study from El-Omar and colleagues,  first 
demonstrated that relatives of patients with gastric cancer, irrespective of the age of 
onset, have an increased prevalence of precancerous gastric abnormalities (34% in 
cancer relatives vs 5% in controls) and hypocloridria (27% in cancer relatives vs 3% in 
controls), but the increase was confined to those with H. pylori infection. In spite of 
that, the increased prevalence of atrophy and hypocloridria in relatives was not 
explained by the increased prevalence of H. pylori infection. Rather, it appeared to be 
the result of an increased propensity to develop atrophy and hypocloridria in response 
to infection. The mean age of gastric cancer relatives at examination was lower than 
the age of the cancer index cases at the diagnosis, which provides insight into changes 
in the gastric mucosa that occurred years before the development of cancer itself (El-
Omar et al. 2000). Other case-control studies confirmed the initial results regarding an 
increased prevalence of preneoplastic changes and H. pylori infection rate in these 
individuals (Brenner et al. 2000, Carneiro et al. 1993, Chang et al. 2002, Eto et al. 2006, 
Jablonska et al. 2001, Leung et al. 2006, Motta et al. 2008, Shin et al. 2010). A recent 
meta-analysis of eleven studies addressed the H. pylori infection and prevalence of 
premalignant conditions and lesions in first degree relatives of gastric cancer patients. 
For the total  of 1500 cases and 2638 controls, the pooled odds ratio with 95% 
confidence interval for H.pylori infection was 1.93 (1.41-2.61), 2.20 (1.27-3.82) for 
atrophy and 1.98 (1.36-2.88) for intestinal metaplasia (Rokkas et al. 2010). Altogether 
current data shows an increased risk for gastric cancer for relatives of gastric cancer 
patients as well as increased prevalence of H.pylori infection and premalignant 
conditions and lesions. Recently, GAPPS (Gastric Adenocarcinoma and Proximal 
Polyposis of the Stomach) was identified as a new hereditary gastric cancer syndrome. 
GAPPS harbors a significant risk of gastric adenocarcinoma and is characterized by 
autossomal dominant transmission of fundic gland polyposis, with areas of dysplasia or 
intestinal type gastric cancer, with no evidence of colorectal or other heritable 
gastrointestinal cancer syndromes (Worthley et al. 2012). 
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IA.6. Early-Onset Gastric Cancer  
It is thought that gastric cancer results from a combination of environmental factors 
and the accumulation of generalized and specific genetic alterations, and consequently 
affects mainly older patients, often after a long period of gastritis (intestinal type 
gastric cancer). Unlike intestinal gastric cancer, the diffuse type typically develops 
following chronic inflammation without passing through the intermediate steps of 
atrophic gastritis or intestinal metaplasia.   
Gastric cancer is rare below the age of 30 years, and thereafter it increases to reach 
the highest rates in the oldest age groups, both in males and females. Early-onset 
gastric cancer (EOCG) is defined as gastric cancer presenting at the age of 45 or 
younger; approximately 10% of gastric cancer patients fall into the EOCG category 
(Kokkola et al. 2001), although rates vary between 2.7% (Umeyama et al. 1982) and 
15% (Ramos-De la Medina et al. 2004). Young patients more frequently develop 
diffuse-type gastric cancer and it is postulated that genetic factors may be more 
important in EOCG than in older patients (Correa et al. 1994, Milne et al. 2007, Milne 
et al. 2009). Environmental factors, such as H.pylori infection, may also play a role in 
the development of the disease in young patients (Haruma et al. 2000, Koshida et al. 
2000, Rugge et al. 1999). Small studies found no association in the distribution of 
gastric cancer predisposing IL1β polymorphisms between young and old patients 
(Sitarz et al. 2008).  
Clinicopathological features of gastric carcinoma are said to differ between young and 
older patients (Maehara et al. 1996), the former claimed to have a poor prognosis 
(Theuer et al. 1996). Also, EOGC tend to be more often multifocal than in older 
patients (Furukawa et al. 1989), as observed also in HDGC (Carneiro et al. 2004). This 
different clinicopathological profiles suggests that EOCG represent a separate entity 
within gastric carcinogenesis and evidence at molecular genetic levels seems to 
support this concept (Milne et al. 2009). The presence of microsatellite instability 
which occurs at a frequency of 15-20% in gastric carcinomas at advanced age seems to 
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be consistently absent in EOCG (Carvalho et al. 2004). Also, APC tumor suppressor 
gene and COX-2 gene does not appear to play an important role in EOCG (Milne et al. 
2006). A higher incidence of aberrant E-cadherin expression in EOCG has also been 
reported although it was correlated only with diffuse type gastric cancer (Milne et al. 
2006). 
Approximately 10% of young gastric cancer patients have a positive family history 
(Kokkola et al. 2001), some of which are accounted for by inherited gastric cancer 
predisposition syndromes. The 90% of EOGC cases without family history emphasizes 
that the occurrence of gastric cancer in young patients remains largely unexplained, 
and is probably due to a predisposing genotype triggered by environmental factors 
(Milne et al. 2009). 
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Gastric Cancer 
Gastric cancer is the fourth most common malignancy in the world. Nowadays, 
stomach cancer is the second leading cause of cancer death in both sexes worldwide 
(736 000 deaths, 9.7% of the total) with only a minority of gastric adenocarcinomas 
diagnosed at a curable and ressectable stage. In Portugal, gastric cancer ranks in 5th 
place in incidence and mortality for both sexes and its incidence and mortality are 
expected to rise in the next years. 
Gastric Cancer Pathways 
Lauren´s classification is the most used for gastric adenocarcinoma because of its 
epidemiologic relevance (Lauren 1965). It encompasses two main histological 
subtypes, diffuse and intestinal, which have different clinicopathological 
characteristics.  
Intestinal type is more frequently observed in older patients and follows a “cascade” 
that begins with multifocal atrophic gastritis after exposure to environmental risk 
factors like H.pylori infection. This is usually accompanied by intestinal metaplasia and 
leads to cancer via dysplasia. This lengthy process, commonly known as “Correa 
Cascade”, is dependent on persistent chronic inflammation (Correa 1992, Correa et al. 
2007).  
Unlike intestinal gastric cancer, the diffuse type typically develops following chronic 
inflammation without passing through the intermediate steps with H.pylori gastritis 
being the only universal precursor condition for this subtype of tumor (Weydig et al. 
2007). A defective intercellular adhesion is a prominent molecular abnormality of 
diffuse carcinomas, resulting from abnormal expression of the cell adhesion protein E-
Cadherin encoded by the CDH1 gene. 
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Risk Factors 
Traditional risk factors for gastric cancer development include diet, salt and nitroso 
compounds consumption and smoking. H. pylori infection is a pivotal risk factor for 
gastric cancer development. Colonization with the bacteria is usually asymptomatic 
and tumor progression only occurs in a subset of individuals and is dependent on the 
host response as well as genetic variation of the bacteria (Atherton 2006). Functional 
differences exist between strains of H.pylori that may relate to virulence and tissue 
damage (Mobley 1996). The well characterized virulence factors are those leading to 
the expression of vacuolating cytotoxin (vacA) and cytotoxin assotiated gene A (cagA). 
Genetic host polymorphisms directly influence inter-individual variation in the 
magnitude of cytokine response and this clearly contributes to an individual´s ultimate 
clinical outcome. The well characterized genetic variations by population-associated 
studies are 1L-1β and IL1 Receptor antagonist (IL-1RN)(El-Omar et al. 2000, Figueiredo 
et al. 2002, Machado et al. 2003) and a single study pointed a possible relevant role of 
the IFNGR1 gene in the development of early-onset gastric cancer (Canedo et al. 2008). 
Premalignant Conditions and Staging 
Several studies showed that gastric cancer risk increases in patients with extensive 
intragastric premalignant conditions (eg, detection both in the antrum and the 
corpus)(Dinis-Ribeiro 2004, Morson 1955, Vannella et al. 2010) which is determined by 
biopsy sampling with histological assessment according to Sydney System (Dixon et al. 
1996). The Sydney updated version recommended five biopsies, one from incisura, two 
from the antrum and two from the corpus, sites that were arbitrarily chosen. Although 
this biopsy protocol is adequate for a correct evaluation of H. pylori status and chronic 
gastritis, the number of biopsies is controversial for an adequate staging of 
premalignant gastric lesions mainly because of their multifocal nature (El-Zimaity et al. 
1999, Eriksson et al. 2005, Guarner 2003, Rugge et al. 2005). The recently established 
OLGA staging system (Operative Link for Gastritis Assessment) aims to translate the 
pathological data into a standardized report with information on the gastric condition 
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(topography and extent of the atrophic changes), subgrouping patients by cancer risk 
(Rugge et al. 2005, Rugge et al. 2008). Acknowledging the fact that severity and 
extension of atrophy remain the main parameter for grading and the interobserver 
agreement is low (Dixon et al. 1996, el-Zimaity et al. 1996), Capelle and colleagues 
(Capelle et al. 2010) introduced a modified OLGA system (OLGIM) based on intestinal 
metaplasia that proved to have a high level of interobserver concordance (Guarner et 
al. 1999). 
Familial Risk and Early-Onset Gastric Cancer  
Familial relative risk is a hallmark of genetic susceptibility but familial clustering may 
also occur because of nonhereditary environmental factors, such as exposure to H. 
pylori, smoking or diet. It is known that 10% of gastric cancers harbor familial 
aggregation, suggesting some kind of familial predisposition. Of these, only 1-3% 
belongs to inherited familial syndromes such as Hereditary Diffuse Gastric Cancer 
(HDGC) (Fitzgerald et al. 2010, Pharoah et al. 2001). The significance of family history 
and familial clustering of gastric cancer is not clearly determined. It was demonstrated 
that having a first-degree relative with gastric cancer is a risk factor for gastric cancer 
with odds ratio (OR) varying from 2 to 10, according to the geographic region and 
ethnicity (Yaghoobi et al. 2009) and  Lauren intestinal type of gastric cancer was 
strongly associated with the family history of gastric cancer when compare with the 
diffuse type (Bernini et al. 2006, Eto et al. 2006). Case-control studies demonstrated 
increased prevalence of preneoplastic changes and H. pylori infection rate in first-
degree relatives of gastric carcinoma patients (Rokkas et al. 2010). 
Early-onset gastric cancer (EOCG) is defined as gastric cancer presenting at the age of 
45 or younger; approximately 10% of gastric cancer patients fall into the EOCG 
category (Kokkola et al. 2001). It is postulated that genetic factors may be more 
important in EOCG than in older patients (Correa et al. 1994, Milne et al. 2007, Milne 
et al. 2009) but environmental factors, such as H.pylori infection, may also play a role 
in the development of the disease in young patients (Haruma et al. 2000, Koshida et al. 
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2000, Rugge et al. 1999). The occurrence of gastric cancer in young patients remains 
largely unexplained, and is probably due to the inter-action between a predisposing 
genotype and environmental triggers (Milne et al. 2009). Relatives of EOGC patients 
were seldom studied. 
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SPECIFIC AIMS 
• To characterize a specific population (First degree relatives of patients suffering 
of gastric carcinoma irrespective of Lauren’s subtype, aged less than 45 years 
old at diagnosis) regarding the histological patterns of gastric mucosa, the 
genetic susceptibility of the individuals and the H.pylori variations responsible 
for the increased risk of developing gastric cancer. A case-control approach was 
used.  
⋅ To determine and quantify the presence of gastric precancerous 
conditions and lesions (histological phenotype). 
⋅ To characterize the H. pylori status and the presence of virulent strains 
(CagA and VacA genes).  
⋅ To determine host gene cluster polymorphisms in the human 
Interleukin 1 Beta (IL-1β), Interleukin 1 Receptor Antagonist (IL-1RN) 
and Interferon Gamma Receptor 1 (IFNGR1) genes.  
 
• To assess OLGA and OLGIM staging systems in the stratification of patients 
according to their cancer risk. 
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SELECTION OF CASES 
Cases included first-degree relatives of early onset gastric carcinoma patients (e.g. 
diagnosed before 45 years).  
Clinical records of all gastric cancer patients treated at Centro Hospitalar do Porto, 
between 2005 and 2010 were examined and age of presentation and data on 
histopathology of noncardia gastric carcinoma were retrieved.  
After exclusion of families with other type of cancers pointing to the possibility of 
hereditary nonpolyposis colorectal cancer (fulfilling Amesterdam II criteria), 40 index 
patients were selected. First-degree relatives (siblings and offspring) were invited to 
participate in the study.  
A maximum of 160 cases (first-degree relatives of the 40 index patients) were 
considered eligible and 103 individuals accepted to be enrolled in the study. In index 
cases, gastric carcinoma was classified as diffuse (n = 20), intestinal (n = 15) and mixed 
(n = 5) according to Lauren classification. 
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DISCUSSION 
The familial clustering of gastric cancer and the significance of family history has been 
addressed in the past (Yaghoobi et al. 2009). Familial relative risk is a hallmark of 
genetic susceptibility but this clustering may also be dependent on non hereditary 
factors, such exposure to H.pylori, diet and smoke. Gastric cancer is thought to result 
from a combination of environmental factors and the accumulation of specific 
molecular alterations due to genetic instability, and consequently affects mainly old 
patients. Many studies examined the molecular genetics and H.pylori infection of 
gastric cancer in general, but very few looked at young patients. Inherited gastric 
cancer predisposition syndromes account for approximately 10% of early-onset gastric 
cancers, the majority of them without an identifiable genetic cause (Kokkola et al. 
2001). Only a very small percentage of early-onset gastric cancers can be explained by 
E-cadherin germline mutations, with only about 30% of all hereditary diffuse gastric 
cancer families carrying CDH1 germline mutations (Oliveira et al. 2004). Some studies 
support the hypothesis that young patients develop carcinomas with a different 
molecular genetic profile from that of sporadic carcinomas occurring at a later age. It is 
postulated that inherited genetic factors may be more important in early onset gastric 
cancer than in gastric cancers found in older patients as they have less exposure to 
environmental carcinogens (Milne et al. 2007, Milne et al. 2010). To the best of our 
knowledge, this study reports for the first time the changes in gastric mucosa and 
host/H. pylori genetic variations of first degree relatives (FDRs) of EOGC patients.  
A case-control study was conducted comparing EOGC relatives to three levels of 
control (spouses, neighbors and dyspeptics). The objective in selecting certain type of 
controls was to sample a representative population, from which the cases arose, 
indicating the background frequency of an exposure in individuals who are free of the 
disease under analysis. We analyzed prior case-control studies using different types of 
controls addressing the familial aggregation role for gastric cancer development. We 
have observed that, independently of the type of control, the risk for the prevalence of 
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premalignant lesions and H pylori infection was higher for the cases which led us to 
conclude that the selection of controls seems to be mainly related to the feasibility of 
recruitment more than to the genetic or environmental background (Marcos-Pinto et 
al. 2012). 
Histological phenotype 
A high rate of premalignant conditions was observed with chronic atrophic gastritis 
(CAG) being diagnosed in 70% of cases and in 34% of the controls (p<0.001). Extensive 
atrophy (e.g. atrophy diagnosed in both antrum and corpus) was present in 58% of 
CAG in cases and in 25% of CAG in controls (p=0.002). The frequency of intestinal 
metaplasia was higher in cases (43%) than in controls (25%) (p=0.002). Also, seven 
cases of dysplastic lesions were detected in cases and none in controls (p=0.007), 
encompassing one high grade dysplasia and six cases of low grade dysplasia (mean age 
- 53 years).  
Premalignant conditions were more prevalent in this sample of relatives of EOGC 
patients than in other series encompassing relatives of gastric cancer patients, 
regardless of the age of onset. In those studies, prevalence of GAC ranges from 11% to 
30% (Brenner et al. 2000, Brenner et al. 2006, Chang et al. 2002, El-Omar et al. 2000, 
Jablonska et al. 2001, Leung et al. 2006, Motta et al. 2008, Rokkas et al. 2010, Shin et 
al. 2010). Recently published guidelines on follow-up of premalignant conditions 
recognized the relevance of family history of gastric cancer and also recommended 
follow-up endoscopy of patients with extensive atrophic changes (follow-up endoscopy 
every 3 years)(Dinis-Ribeiro et al. 2012). In our study more than half of cases (with a 
mean age of 43 years) had extensive atrophy and would be amenable for follow-up 
according to the aforementioned guidelines. 
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Premalignant Conditions Staging  
OLGA staging 
OLGA gastritis classification system aims to translate the histopathological data into  a 
standardized report (with information on topography and extent of the atrophic 
changes) and sub grouping patients by cancer risk (those included in stages III and IV 
harboring the highest  risk for gastric cancer development, therefore being eligible for 
follow-up) (Rugge et al. 2008), as suggested in two cross sectional studies (Rugge 2003, 
Satoh et al. 2008). Recently, a 12 year follow up study gave additional support to the 
initial results (Rugge et al. 2010) and showed also a  relationship of stages III-IV with 
lower pepsinogen I/II ratio, a marker of gastric extensive atrophy (Daugule et al. 2011, 
Rugge et al. 2010). Intestinal metaplasia subtyping was also shown to be incorporated 
in high-risk OLGA stages (III and IV) with sulfomucin-type intestinal metaplasia (type III) 
being associated with an increased risk of gastric cancer (Rugge et al. 2011). In our 
study, the first case-control study applying OLGA staging to a high-risk population, 19% 
of cases (FDRs of EOGC patients) clustered in stages III-IV compared to 0% of the 
controls (p<0.001), showing that there was a high number of patients with extensive 
atrophy, thus eligible for follow-up. All peptic ulcers were included in low-risk stages 
and 86% of dysplastic lesions clustered in stages III-IV (p<0.005).  
OLGIM staging 
It has been recognized that a potential drawback of OLGA staging is the fact that it 
relies in the severity and extent of gastric atrophy, a parameter for which there is low 
inter-observer agreement (Chen et al. 1999, Dixon et al. 1996, el-Zimaity et al. 1996). 
Capelle et al proposed a classification system (OLGIM) that uses only one of the 
phenotypic expressions of atrophy (intestinal metaplasia), achieving an higher inter-
observer agreement (K=0.9 for intestinal metaplasia and K=0.6 for atrophic gastritis) 
and a downgrade of stages leading to a smaller population suitable for surveillance 
(Capelle et al. 2010). Recently, Rugge et al conducted a retrospective, non 
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standardized study, encompassing 4,552 consecutive biopsy sets, aiming at the 
comparison of OLGA and OLGIM classification systems (Rugge et al. 2011). Inter-
observer agreement was found to be higher for OLGIM than for OLGA system and the 
use of the former resulted in a 6.6% downgrade of stages in comparison with OLGA 
classification. In both staging systems, a significant association was observed between 
stages III-IV and gastric neoplasia (Rugge et al. 2011).    
In our study, 44% of cases were scored as stages I-IV according to OLGIM with a 27% 
downgrade in comparison with OLGA. In stages III-IV, there was a 3% downgrade of 
staging, without interfering with the clustering of dysplasia (86%) in high-risk stages, 
which is in keeping with the results obtained by the proponents of the OLGIM system 
(LG Capelle et al. 2010).  
Modified OLGA and OLGIM staging (excluding incisura angularis biopsy) 
The value of the diagnostic yield of the biopsy of incisura angularis has been addressed 
in several studies. Despite being considered the location affected at the onset of 
atrophy/metaplastic transformation (Ricuarte 2005, Rugge 2003), at least two studies 
concluded that few histological findings were detectable only in biopsies of the 
incisura angularis (Eriksson et al. 2005, Satoh et al. 1998). These results suggest that 
more important that the site where the atrophic transformation begun is its extension, 
the latter being the parameter that confers gastric cancer risk (Cassaro et al. 2000, 
Dinis-Ribeiro et al. 2004, Filipe et al. 1994). Guidelines recently proposed for the 
follow-up of gastric premalignant conditions and lesions suggested the exclusion of the 
biopsy of the incisura angularis for staging, keeping two  biopsies of the antrum and 
other two biopsies of the corpus (Dinis-Ribeiro et al. 2012). In the group of FDRs of 
EOGC patients, using modified OLGA and modified OLGIM staging systems (with 
exclusion of the biopsy of incisura angularis), we observed, respectively, 15% and 30% 
downgrade of staging in comparison with the original OLGA system. Equal and less 
pronounced downgrade of staging was observed in high-risk (5 %) for both for both 
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modified staging systems in comparison with OLGA system. A relevant fact is that for 
all staging systems, advanced lesions (e.g.dysplasia) cluster in high-risk stages. 
 
Helicobacter pylori infection 
We observed a higher prevalence of H. pylori infection in relatives of gastric cancer 
patients than in controls (82% vs. 62%) (p=0.004). These results are in keeping with 
previous data that showed increased prevalence of infection in relatives of gastric 
cancer patients (Brenner et al. 2000, El-Omar et al. 2000, Leung et al. 2006, Motta et 
al. 2008, Shin et al. 2010). Regarding the pathogenicity of H. pylori strains, we found no 
global difference in prevalence of strains harboring cagA pathogenic factor or vacAs1, 
vacAm1 strains. However, at advanced OLGA stages (III and IV) we found an increased 
prevalence of virulent strains (vacAs1, vacAm1).  These results are also in agreement 
with those obtained by Li et al, showing a high prevalence of specific H. pylori 
pathogenic strains in a series of 38 first degree relatives of gastric cancer patients 
population (Li et al. 2002). Other studies demonstrated that H. pylori probably play a 
relevant role in the development of gastric cancer in young patients but in a smaller 
percentage than in the older age group (Koshida et al. 2000, Rugge et al. 1999).  
Host genetic variations 
Regarding the host genotype no significant differences were found between cases and 
controls for frequency of specific polymorphisms of IL1B and IL1RN genes. 
Interestingly, a significant association was found between IL1B-511 *T/T polymorphism 
and gastric dysplasia (p<0.001). Our results corroborate those previously reported by 
El-Omar et al (El-Omar et al. 2000) in relatives of gastric cancer patients, in which, 
similarly to our findings, there was not a significant increase of proinflammatory gene 
polymorphisms. Nevertheless, among the infected gastric cancer relatives with low 
gastric acid secretion, El-Omar et al found a significantly higher frequency of some 
proinflammatory polymorphisms (IL-1RN *2/*2 and IL-1B-511 *T carrier status)(El-
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Omar et al. 2000). On the other hand a Chinese study found an increased prevalence 
of IL-1B-511 *T and IL-1RN *2 genotype prevalence in first degree relatives of gastric 
cancer patients, irrespective of the age of onset; the study did not assess gastric 
histopathology (Feng et al. 2008). Sitarz et al observed no difference in the distribution 
of gastric cancer predisposing IL1B polymorphisms (IL-1B-31T)  between young and 
older patients (Sitarz et al. 2008).  
We observed an increased genotype frequency of IFN-γ 1receptor (IFNGR1) (56C/T) – 
T*/*T in FDRs of EOGC patients. It was demonstrated that an upregulated production 
of IFN-γ is relevant in promoting H. pylori induced mucosal inflammation (Smythies et 
al. 2000). Genome-wide linkage analysis first identified a polymorphism of the 
IFNGR1gene associated with an increase in the susceptibility to H. pylori infection 
(Thye et al. 2003). These results are consistent with those obtained by Canedo et al 
study in two different populations showing that homozygosity for IFNGR1-56*T allele 
is a risk factor for the developing of early onset gastric cancer (OR: 4.1)(Canedo et al. 
2008). 
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CONCLUDING REMARKS 
Our findings showing that premalignant lesions and H. pylori infection are more 
prevalent in cancer relatives support a role for these abnormalities in the sequence of 
events leading to gastric cancer. The increased prevalence of premalignant lesions was 
partially explained by the presence of specific H. pylori pathogenic strains in advanced 
OLGA stages and by the significant association of IL1B *T/T host polymorphism with 
gastric dysplasia. Furthermore, our results suggest that some polymorphisms of IFNGR 
gene (homozygosity for the T allele) may be a risk factor for the development of EOGC. 
An alternative hypothesis would be that genetic susceptibility factors (e.g. specific 
polymorphisms of IFNGR1gene) may play a role in the development of EOGC, while 
environmental factors (H. pylori infection, diet, etc.) and their cumulative effect an 
important contribution for the development of gastric cancer at an older age. 
Our results further support the important clinical issue of H.pylori eradication in first 
degree relatives of gastric cancer patients. It has been described for relatives of gastric 
cancer patients that eradication of H.pylori resolves inflammatory gastritis and 
restores normal structure and secretory function to half of those with hypocloridria 
and low severity grade of atrophy before treatment (El-Omar et al. 2000). Other 
studies assessed the benefit of H.pylori eradication for the prevention of  gastric 
cancer and even though they failed to show a benefit, the subgroup analysis showed a 
substantial reduction in the incidence of gastric cancer for patients without 
premalignant conditions and lesions  such as atrophic gastritis, intestinal metaplasia 
and dysplasia (Rokkas et al. 2007, Wong et al. 2004). Taking into account that chronic 
atrophic gastritis develops in gastric mucosa of FDRs of EGC patients by the ages of 20-
30 years, early eradication should be provided, at least for this population.  
A relevant issue regarding gastric cancer risk is screening. Several uncontrolled trials 
suggested that cancer mortality has been reduced in Japan where a nationwide mass 
screening program was implemented (Fukao et al. 1995, Lee et al. 2006). However, a 
mass-screening program in countries with low incidence of gastric cancer is not 
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appropriate considering the costs, ethical issues and the burden for the Health system 
and for the patients. It has been suggested that a case-finding approach would be 
suitable (de Vries et al. 2007) with family history of gastric cancer being an inclusion 
factor. Recently published guidelines on follow-up of premalignant conditions 
recognized the relevance of family history of gastric cancer and also recommended 
follow-up endoscopy of patients with extensive atrophic changes (follow-up endoscopy 
every 3 years)(Dinis-Ribeiro et al. 2012). In our study more than half of cases (with a 
mean age of 43 years) had extensive atrophy and would be amenable for follow-up 
according to the aforementioned guidelines. The optimal schedule for these patients 
and the age of first endoscopy needs to be elucidated.  
Additionally, new endoscopic imaging equipments and methods such as Narrow Band 
Imaging (NBI) may improve the identification and characterization of these 
premalignant lesions and help to target biopsy sampling in high risk groups such as 
FDRs of EOGC patients. This might allow a more accurate screening, follow-up of high 
risk groups and, eventually, the diagnosis of early neoplasia amenable of endoscopic 
resection. Recently, we demonstrated that NBI endoscopy may be a reproducible and 
accurate method for the diagnosis of gastric pre-neoplastic and cancer lesions. Indeed, 
some NBI features were very reproducible and were associated consistently with 
gastric lesions. A simplified NBI classification was accurate and reliable for the 
diagnosis of intestinal metaplasia and dysplasia (Pimentel-Nunes et al. 2012). 
The translation of these observations to clinical practice leads to the recommendation 
for H. pylori eradication in FDRs of EOGC and endoscopic screening with at least four 
biopsies in antrum and corpus to allow adequate staging and follow-up of 
premalignant conditions and lesions scored in high-risk stages and regular follow-up 
for the relatives with extensive gastric atrophy. 
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The present work described, for the first time, a high risk population for gastric 
cancer development with a unique genetic and histophatological phenotype 
with possible clinical impact. It represents an open way for new comprehensive 
studies: 
 We demonstrated that FDRs of EOGC had a high rate of premalignant 
conditions and lesions (atrophy, intestinal metaplasia and dysplasia); a 
cohort study is now needed to determine the accurate rate of 
progression in the carcinogenic cascade than the same conditions in the 
general population. This cohort study could also validate the risk 
stratification conferred by OLGA/OLGIM and its modified versions 
regarding gastric cancer risk, namely in this setting. 
 We demonstrated in FDRs of EOGC a specific host genotype regarding 
proinflammatory profile. Other genetic variations previously described 
in early-onset gastric cancer such as prostate stem cell antigen (PSCA) 
and a cell membrane-bound mucin protein Mucin 1 (MUC1) gene would 
be candidate genes for association studies. 
 We studied the classic H.pylori virulence factors (cagA, vacA) and the 
association with premalignant conditions and lesions. New virulence 
factors could be investigated, such as virulence-associated vacA 
intermediate (i) region and CagA Glu-Pro-Ile-Tyr-Ala (EPIYA) virulence 
factors. 
 The prevalence of premalignant conditions and lesions was defined by 
histophatological samples. As we demonstrated, new endoscopic 
methods are highly specific and reproducible for the diagnosis of 
intestinal metaplasia and dysplasia. The screening of such high risk 
population with those new endoscopic methods could help to validate 
their role in diagnosing dysplasia and early gastric cancers amenable to 
endoscopic resection and cure. 
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FDRs. First Degree Relatives 
EOGC. Early-Onset Gastric Cancer 
CDH1. E-Cadherin 
HDGC. Hereditary Diffuse Gastric Cancer  
H.pylori. Helicobacter pylori 
vacA. Vacuolating Cytotoxin  
cagA. Cytotoxin Associated Gene A  
IL-1RN. Interleukin 1 Receptor Antagonist 
IL-1β. Interleukin 1 β  
IFNGR1. Interferon γ Receptor 1   
AG. Atrophic Gastritis 
CAG. Chronic Atrophic Gastritis  
IM. Intestinal Metaplasia  
OLGA. Operative Link for Gastritis Assessment 
OLGIM. Operative Link for Gastric Intestinal Metaplasia 
PG. Serum Pepsinogen 
GAPPS. Gastric Adenocarcinoma and Proximal Polyposis of the Stomach 
 
 
